Acknowledgments:
We would like to acknowledge the pathologists of Brest and Quimper and the Local tumor tissue biobank BB-0033-00037 (“CRB Santé/Tumorothèque de Brest”) for their collaboration.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Potrony M, Badenas C, Naerhuyzen B, Aguilera P, Puig-Butille JA, Tell-Marti G, et al. Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas. Clin Chem Lab Med 2016. doi: 10.1515/cclm-2015-1048 [Epub ahead of print].Search in Google Scholar PubMed
2. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013;15:94–100.10.1016/j.jmoldx.2012.09.001Search in Google Scholar PubMed
3. Long E, Ilie M, Lassalle S, Butori C, Poissonnet G, Washetine K, et al. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). J Eur Acad Dermatol Venereol 2015;29:2436–43.10.1111/jdv.13332Search in Google Scholar PubMed
4. Uguen A, Talagas M, Costa S, Samaison L, Paule L, Alavi Z, et al. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Diagn Pathol 2015;10:121.10.1186/s13000-015-0359-0Search in Google Scholar PubMed PubMed Central
5. Uguen A, Gueguen P, Legoupil D, Bouvier S, Costa S, Duigou S, et al. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. Hum Pathol 2015;46:1582–91.10.1016/j.humpath.2015.06.023Search in Google Scholar PubMed
6. Fisher KE, Cohen C, Siddiqui MT, Palma JF, Lipford EH, Longshore JW. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol 2014;45:2281–93.10.1016/j.humpath.2014.07.014Search in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
